Skip Ribbon Commands
Skip to main content
Clin Asst Prof Ng Chau Hsien Matthew

Clin Asst Prof Ng Chau Hsien Matthew

MBBS (London), MRCP (UK), PhD (UK)

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology, Medical Oncology

Clinical Interest: Colorectal, Upper Gastrointestinal, Peritoneal-based Malignancies, Liver, Pancreatic and Bile Duct, Gastrointestinal Oncology

Conditions Treated by this Doctor:
Bile Duct Cancer, Biliary Tract Cancer, Colorectal Cancer, Liver Cancer, Oesophagus Cancer, Pancreatic Cancer, Peritoneal based Malignancies, Stomach Cancer.

Clinical Appointments

  • Senior Consultant and Head of Department of GI Oncology Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Clinical Director Investigational Medicine Unit (SingHealth)

Academic Appointments

  • Clinical Asst Professor, Duke-NUS Medical School


Dr Matthew Ng is the Head of GI Oncology at the National Cancer Centre Singapore and obtained his PhD from the Institute of Cancer Research (London, UK). He is the lead for Upper GI cancers, Director of the Investigational Medicine Unit for early phase trials. His research interest is in developing novel treatments for GI cancers.


  • PhD (UK), Institute of Cancer Research 
  • M.R.C.P (UK), Royal College of Physicians, UK 
  • MBBS (London), St. Bartholomew’s and Royal London Hospital School of Medicine and Dentistry

Professional Appointments and Committee Memberships

  • Co-Chair Cancer Service Line Delivery for GI cancers (Singhealth)
  • Chair Named Patient Programme (NCCS)


  • Brackenbury and Bourne Scholarship in Clinical Medicine, 2000 
  • Heath Skynner Prize in Paediatrics, 2000 
  • Draper's Prize for academic achievement 
  • Proxime Accessit to the University of London Gold Medal

Research Interests

  • Early phase clinical trials incorporating biomarker analyses/development 
  • Developing biomarkers for diagnostics and therapeutics for GI cancers


• Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkata-narasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23. [IF: 4.9]
• Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH,  Tham CK, Lam J, Koo SL, Chong HS, Goh G, Huang HL, Venkatanarasim-ha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim T, Yeong J, Zhai W, Chan CY, Choo SP. A Phase II Single Arm, Single Centre Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinoma– CA 209-678. Lancet Gastroenterology and Hepatology 2021 (accepted) [IF: 4.9 ]
• Finkelstein EA, Baid D, Cheung YB, Schweitzer ME, Malhotra C, Volpp K, Kanesvaran R, Lee LH , Dent RA, Ng MCH, Mohamad Farid BHR, Somasundaram S.
Hope, bias and survival expectations of advanced cancer patients: A cross-sectional study. Psychooncology. 2021.  May;30(5):780-788. doi: 10.1002/pon.5675. Epub 2021 Apr 1.[IF: 3.9]
• Khin NS, Tan SH, Wang MLC, Siow TR, Lim F, Wang FQ, Ng MCH, Lam JYL, Yip C. Chemoradiation-induced changes in systemic inflammatory markers and their prognostic sig-nificance in oesophageal squamous cell carcinoma. Br J Radiol. 2021. doi:10.1259/bjr.20200314. Epub 2021 Apr 16. [IF: 3.0]
• An O, Song Y, Ke X, So JB-Y, Sudar R, Yang H, Rha SY, Lee MH, Tay ST, Ong XW, Tan ALK, Ng MCH, Tantoso E, Chen LL, Tan P, Yong WP, Singapore Gastric Cancer Consorti-um (SGCC). 
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Can Res 2021; 81:2788 [IF: 12.7]
• Seet AO, Tan AC, Ng MCH, Tai DWM, Lam JYC, Tan GS, Gogna A, Too CW, Tanako A, Lim A, Tan BS, Lim TH, Lim ST, Dent RA, Ang MK, Yap YS, Tan IBH, Choo SP, Toh CK, Lim EH, Mohamad FBH, Skanderup AJ, Iyer NG, Lim WT, Lim TKH, Tan DSW.
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore (IMPACT-SG) Study – an Asian tertiary cancer center experience. JCO Precision Oncology 2021. 5:859
• Shimizu T, Kim D-W, Loong HH, Lin C-C, Yamato Noboru, Ng CH, Ma Bridgette, Tan Dan-iel SW. Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and development in Asia – experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. Asia Pac J Clin Oncol. 2021. 17:388-395.  [IF: 2.6]
• Tan AC, Seet AO, Lai GG, Lim TH, Lim AS, Tan GS, Takano A, Tai DW, Tan TJ, Lam JY, Ng MCH , Tan WL, Ang MK, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim WT, Tan EH, Lim TKH, Tan DSW. 
Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC). J Thoracic Onc. Epub 27Aug 2020 [IF: 15.6] [Times cited: 14]
• Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ; CP-MGAH22-5 Study Group.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020 Aug;21(8):1066-1076. doi: 10.1016/S1470-2045(20)30326-0. Epub 2020 Jul 9. [IF: 41.3]
• Muro K, Van Custem E, Narita Y,  Pentheroudakis G,  Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli R, Smyth EC, Arnold D, Minami H, Tabenero J, Douillard al.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals Onc. 2019. 30:19-33 [IF 18.3]
• Lam JYC, Choo SP, Tai DW, Tan IBH, Tham CK, Koo WH, Ong SYK, Ang SF, Chua CWL, Chong DQ, Teo PTH, Lee CJZ, Ee SCE, Ng MCH.
What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center. Asia Pac J Clin Oncol. 2020 Feb;16(1):23-27. doi: 10.1111/ajco.13285. Epub 2019 Nov 17. [IF: 2.6]
• Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x. [IF: 12.1]
• Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani A et al:
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer 108:17-24, 2019 [IF: 7.3]
• Hyman DM, Tran B, Paz-Ares L, Machiels JP, Schellens JH, Bedard PL, Campone M, Cassier PA, Sarantopoulos J, Vaishampayan U, Chugh R, Mahipal A, Lockhart AC, Sessa C, Zander T, Ng M, Curigliano G, Bendiske J, Chen X, Choudhury S, Grau-Porta D, Lewis N, Garcia JMP, Miguel-Luken MJ et al:
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncolo-gy:1-13, 2019
• Tan RYC, Camat MD, Ng M, Lim AS, Lim KH, Tan IBH.
HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients. Annals Onc 2018. 29:1598 [IF: 14.2] [Times cited: 2]
• Tan HL, Chia CS, Tan GHC, Choo SP, Tai DW, Chua CWL, Ng MCH, Soo KC, Teo MCC. Metastatic gastric cancer: Does the site of metastasis make a difference? Asia Pac J Clin On-col. 2019 Feb;15(1):10-17. doi: 10.1111/ajco.13025. Epub 2018 Jun 19. [IF: 2.0]
• Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25. [IF: 8.9]
• Tan HL, Chia CS, Tan GH, Choo SP, Tai DW, Chua CW, Ng MC, Soo KC, Teo MC.
Gastric peritoneal carcinomatosis - a retrospective review. World J Gastrointest Oncol. 2017 Mar 15;9(3):121-128 [IF: 3.1]
• Ng SB, Chua C, Ng M, Gan A, Poon PS, Teo M, Fu C, Leow WQ, Lim KH, Chung A, Koo SL, Choo SP, Ho D, Rozen S, Tan P, Wong M, Burkholder WF, Tan IB.
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep. 2017 Jan 19;7:40737. [IF: 4.1]
• Chong DQ, Manalo M, Imperial M, Teo P, Yong G, Ng M, Tan IB, Choo SP, Chua C.
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin, and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. Asia Pacific J of Oncolo-gy. 2016. Sep;12(3):275-83. [IF: 2.0]
• Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP.
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.  Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. [IF: 2.8]
• Nathan P, Zweifel M, Padhani A, Koh D, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Taylor NJ, Stirling JJ, Lu SP, Leach MO, Rustin GJ, Judson I.
Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clin Cancer Res. 2012 Jun 15;18(12):3428-39. [IF: 7.8]
• Ng M, Cunningham D, Norman A. 
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer. Eur J Cancer 2005. 41:1542-46 [IF: 3.7]
• Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005.  92:1352-7 [IF: 4.1]

Research Trials

  • Phase 1 Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] as Treatment in Patients with Advanced and/or Metastatic Pancreatic Adenocarcinoma 
  • A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer 
  • Phase I study to evaluate the safety and tolerability of ASLAN001 in combination with Oxaliplatin and Capecitabine 
  • A Phase 1A/B study to evaluate the safety and tolerability of ETC-1922159 in advanced solid tumours